## Labcorp Oklahoma, Inc. Test Directory

## VistaSeq Breast and GYN Cancer

Order Name: Breast/GYN Ca

Test Number: 5194365 Revision Date: 01/01/2025

TEST NAME		METH	ODOLOGY	LOINC CODE	
VistaSeq Breast and GYN Cancer		See T	See Test Notes		
SPECIMEN REQUIREMENTS					
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment	
Preferred	10 mL (7 mL)	Whole Blood	EDTA (Lavender Top)	Room Temperature	
Alternate 1	10 mL (7 mL)	Whole Blood	ACD Solution A or B (Yellow Top)	Room Temperature	
Alternate 2	2 mL (0.5 mL)	Saliva	See Instructions	Room Temperature	
Instructions	Notes: 7 mL whole blood, 0.5 mL saliva  Specimen Type: Lavender-top (EDTA) tube OR yellow-top (ACD) tube OR Oragene DX 500 saliva collection kit.  Specimen Storage: Room temperature  Specimen Collection: Blood is collected by routine phlebotomy. Saliva is collected by spitting into the provided container until it reaches the fill line.  Special Instructions: A clinical questionnaire should be submitted with all specimens. Contact CMBP genetic services at 800-345-4363 to coordinate testing.  Specimen Stability: Ambient: 60 days, Refrigerated: 60 days, Frozen: Not Available  Causes for Rejection: Frozen specimen; leaking tube; clotted specimen; grossly or hemolyzed specimen; quantity not sufficient for analysis;				

See Oragene Dx 500 saliva kit for detailed instructions.

incorrect anticoagulant; saliva collection in an incorrect container. Do not eat, drink, smoke, or chew gum 30 minutes prior to saliva sample collection.

GENERAL INFORMATION			
Expected TAT	24 - 28 days		
Clinical Use	Test Includes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, FANCC, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11 and TP53.  ?Synonyms: Familial Cancer testing Hereditary Cancer testing Inherited Cancer testing		
Performing Labcorp Test Code	481341		
Notes	Labcorp Test Code: 481341  Methodology: The coding region and flanking splice sites are analyzed by NGS (+/-10bp) and deletion/duplication analysis. Exon-level deletions/duplications are assessed by aCGH or by MLPA. Analysis is limited to deletion/duplication testing for EPCAM. Analysis is expanded for BRCA1/2 flanking splice sites (+/-20bp) and to include promoter sequence variants for PTEN (c1300 to c750). Clinically significant findings are confirmed by Sanger sequencing or qPCR. Results are reported using ACMG guidelines and nomenclature recommended by the Human Genome Variation Society (HGVS).  Click Here to view on Labcorp test directory		
CPT Code(s)	81432		
Lab Section	Reference Lab		

Service provided by Labcorp Oklahoma, Inc. All Rights Reserved. © 2003 - 2025